A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)

Bibliographic Details
Title:	A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)
Authors:	Drummond, Mark W ^, Harrison, Claire N., Munoz Vicente, Samuel ^, Mead, Adam J, Yap, Christina ^, Chen, Frederick ^, Narayanan, Srinivasan ^, Milojkovic, Dragana ^, Navarro-Nunez, Leyre ^*, Knapper, Steven
Source:	In Blood 8 December 2017 130 Supplement 1:1649-1649
Database:	ScienceDirect